A5056034076- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Neurological Disease Mechanisms and Treatments
- Health, Environment, Cognitive Aging
- Advanced Neuroimaging Techniques and Applications
- Neurological Disorders and Treatments
- Memory and Neural Mechanisms
- Diet and metabolism studies
- Frailty in Older Adults
- Health disparities and outcomes
- Spatial Neglect and Hemispheric Dysfunction
- Epilepsy research and treatment
- Cancer-related cognitive impairment studies
- Machine Learning in Healthcare
- Schizophrenia research and treatment
- Bioinformatics and Genomic Networks
- Parkinson's Disease Mechanisms and Treatments
- COVID-19 and Mental Health
- Olfactory and Sensory Function Studies
- Intensive Care Unit Cognitive Disorders
- Neuroscience and Neuropharmacology Research
- Mental Health Research Topics
- Brain Tumor Detection and Classification
- Tryptophan and brain disorders
Harvard University
2016-2025
Brigham and Women's Hospital
2016-2025
Massachusetts General Hospital
2016-2025
San Francisco VA Medical Center
2024
University of California, San Francisco
2024
Athinoula A. Martinos Center for Biomedical Imaging
2010-2023
Alzheimer’s Disease Neuroimaging Initiative
2022-2023
Gordon Center for Medical Imaging
2023
Maastricht University
2023
Transnational University Limburg
2023
Objective Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis Alzheimer disease (AD), staging and monitoring progression, development disease‐modifying therapies. Methods We acquired positron emission tomography (PET) using 18 F T807 (AV1451), amyloid‐β PET 11 C Pittsburgh compound B (PiB) in older clinically normal individuals, symptomatic patients with mild cognitive impairment or AD dementia. Results found abnormally high cortical binding...
Positron emission tomography (PET) imaging now allows in vivo visualization of both neuropathologic hallmarks Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau neurofibrillary tangles. Observing their progressive accumulation the brains clinically normal older adults is critically important to understand pathophysiologic cascade leading AD inform choice outcome measures prevention trials.To assess associations among Aβ, tau, cognition, measured during different observation periods for 7...
Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) promising candidate for treating human AD. The purpose current study generate tolerability preliminary clinical biomarker efficacy data curcumin persons with AD.We performed 24-week randomized, double blind, placebo-controlled...
Impairment in instrumental activities of daily living (IADL) leads to early loss productivity and adds significant burden caregivers. Executive dysfunction is thought be an important contributor functional impairment. The objective this study was investigate the relationship between executive function IADL a large cohort well-characterized normal older controls, mild cognitive impairment (MCI), patients with Alzheimer's disease, separately as well across entire sample, while accounting for...
To examine reciprocal relations of loneliness and cognitive function in older adults.Data were analyzed from 8382 men women, age 65 older, participating the US Health Retirement Study 1998 to 2010. Participants underwent biennial assessments depression (classified as no, low or high depression) determined by Center for Epidemiologic Studies Depression scale (8-item version), cognition (a derived memory score based on a word list task proxy-rated global function), health status social...
Both amyloid-β (Aβ) deposition and brain atrophy are associated with Alzheimer's disease (AD) the process likely begins many years before symptoms appear. We sought to determine whether clinically normal (CN) older individuals Aβ revealed by positron emission tomography (PET) imaging using Pittsburgh Compound B (PiB) also have evidence of both cortical thickness hippocampal volume reductions in a pattern similar that seen AD. A total 119 (87 CN subjects 32 patients mild AD) underwent PiB PET...
Alzheimer's disease (AD) is associated with functional and structural alterations in a distributed network of brain regions supporting memory other cognitive domains. Functional abnormalities are present mild impairment (MCI) evidence early hyperactivity medial temporal lobe regions, followed by failure hippocampal activation as dementia develops. Atrophy consistent set cortical the “cortical signature AD,” has been reported at stage dementia, MCI, even clinically normal (CN) older...
Objectives Amyloid‐beta (Aβ) and tau pathologies are commonly observed among clinically normal older individuals at postmortem can now be detected with in vivo neuroimaging. The association interaction of these proteinopathies prospective cognitive decline aging preclinical Alzheimer's disease (AD) remains to fully elucidated. Methods One hundred thirty‐seven (age = 76.3 ± 6.22 years) participating the Harvard Aging Brain Study underwent Aβ ( 11 C‐Pittsburgh compound B) 18 F‐flortaucipir)...
Cross-sectional functional magnetic resonance imaging studies using a memory task in patients with mild cognitive impairment have produced discordant results, some reporting increased hippocampal activity—consistent findings genetic at-risk populations—and other decreased activity, relative to normal controls. However, previous not included markers of amyloid-β, which may be particularly important prediction progression along the Alzheimer's disease continuum. Here, we examine contribution...
Objective: To understand the role of depressive symptoms in preclinical Alzheimer’s disease, it is essential to define their temporal relationship proteinopathies cognitively normal older adults. The study objective was examine associations brain amyloid beta and longitudinal measures depression symptom clusters a sample Method: A total 270 community-dwelling, elderly individuals underwent baseline Pittsburgh compound B (PiB) positron emission tomography (PET) cortical aggregate annual...
Emotional and behavioral symptoms in cognitively normal older people may be direct manifestations of Alzheimer disease (AD) pathophysiology at the preclinical stage, prior to onset mild cognitive impairment. Loneliness is a perceived state social emotional isolation that has been associated with functional decline an increased risk incident AD dementia. We hypothesized loneliness might occur association elevated cortical amyloid burden, vivo research biomarker AD.To determine whether burden...
Identifying asymptomatic individuals at high risk of impending cognitive decline because Alzheimer disease is crucial for successful prevention dementia. Vascular and β-amyloid (Aβ) pathology commonly co-occur in older adults are significant causes impairment.To determine whether vascular Aβ burden act additively or synergistically to promote clinically normal adults; and, secondarily, evaluate the unique influence on prospective beyond that used imaging biomarkers, including burden,...
Trials of monoclonal antibodies that target various forms amyloid at different stages Alzheimer's disease have had mixed results. Download a PDF the Research Summary. We tested solanezumab, which targets monomeric amyloid, in phase 3 trial involving persons with preclinical disease. Persons 65 to 85 years age global Clinical Dementia Rating score 0 (range, 3, indicating no cognitive impairment and severe dementia), on Mini–Mental State Examination 25 or more 30, lower scores poorer...
<h3>Importance</h3> Neurofibrillary tangles composed of aggregated tau protein are one the neuropathological hallmarks Alzheimer disease (AD) and correlate with clinical severity. Monoclonal antibodies targeting may have potential to ameliorate AD progression by slowing or stopping spread and/or accumulation pathological tau. <h3>Objective</h3> To evaluate safety efficacy monoclonal anti-tau antibody semorinemab in prodromal mild AD. <h3>Design, Setting, Participants</h3> This phase 2...
Accumulation of tau pathology in Alzheimer disease (AD) correlates with cognitive decline. Anti-tau immunotherapies were proposed as potential interventions AD. While antibodies targeting N-terminal failed to demonstrate clinical efficacy prodromal-to-mild AD, their utility at other stages was not evaluated prior studies. Lauriet is a phase 2 study an anti-tau monoclonal antibody, semorinemab, patients mild-to-moderate
Background: Apathy is the most common neuropsychiatric manifestation in Alzheimer disease (AD).Clinical, single-photon emission computed tomography, magnetic resonance imaging, and pathologic studies of apathy AD have suggested an association with frontal dysfunction, supportive anterior cingulate abnormalities, but without a definitive localization.Objective: To examine between cortical metabolic rate on positron tomography AD.Design: Forty-one subjects probable underwent [ 18 F]...
<h3>Importance</h3> Several large-scale Alzheimer disease (AD) secondary prevention trials have begun to target individuals at the preclinical stage. The success of these depends on validated outcome measures that are sensitive early clinical progression in who initially asymptomatic. <h3>Objective</h3> To investigate utility Cognitive Function Instrument (CFI) track changes cognitive function older without impairment baseline. <h3>Design, Setting, and Participants</h3> Longitudinal study...
Abstract Introduction Sensitive detection of cognitive decline over the course preclinical Alzheimer's disease is critical as field moves toward secondary prevention trials. Methods We examined amyloid β (Aβ)‐related change in several variations Alzheimer composite (PACC) and each individual PACC component clinically normal (CN) older participants Harvard Aging Brain Study. then Disease Cooperative Study Prevention Instrument a replication cohort. Results Aβ+ CN individuals demonstrated...
<h3>Objective:</h3> To determine whether neuroimaging biomarkers of amyloid-β (Aβ) and neurodegeneration (ND) are associated with greater self-reported subjective cognitive concerns (SCC) in clinically normal older individuals. <h3>Methods:</h3> A total 257 participants underwent Pittsburgh compound B PET, PET fluorodeoxyglucose <sup>18</sup>F, structural MRI, as well a battery neuropsychological measures including several questionnaires regarding SCC. Individuals were classified into 4...
Impairment in activities of daily living (ADL) accompanies cognitive and behavioral symptoms Alzheimer's disease (AD). Conventionally, ADL impairment has been relegated to the stage dementia, but instrumental shown occur earlier at mild (MCI). There are many subjective performance-based scales, some which useful distinguishing between MCI AD even clinically normal elderly individuals. These scales have associated with amyloid neurodegeneration biomarkers AD. Clinically individuals who a...
Our objective was to investigate cross-sectional associations between odor identification ability and imaging biomarkers of neurodegeneration amyloid deposition in clinically normal (CN) elderly individuals, specifically testing the hypothesis that there may be an interaction predicting dysfunction.Data were collected on 215 CN participants from Harvard Aging Brain Study. Measurements included 40-item University Pennsylvania Smell Identification Test neuropsychological testing, hippocampal...
Neuropsychiatric symptoms in Alzheimer's disease (AD) are highly prevalent. We sought to determine whether neuropsychiatric were related global functional impairment at baseline and over a 3-year period older normal control (NC), mild cognitive (MCI) AD dementia subjects.Eight hundred twelve subjects (229 NC, 395 MCI, 188 AD) from the Disease Neuroimaging Initiative study underwent behavioral assessments 3 years.Greater hallucinations, anxiety apathy associated with greater baseline, while...